| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GLSH | Convertible Note | Purchase | $25T | +5M | $5,000,000.00* | 5M | May 1, 2023 | Common Stock | 18.6M | $0.27 | By PureTech Health LLC | F1, F2 | |
| transaction | GLSH | Convertible Note | Purchase | $4T | +2M | $2,000,000.00* | 2M | May 1, 2023 | Common Stock | 110M | $0.02 | By PureTech Health LLC | F2 | |
| transaction | GLSH | Warrants | Purchase | +23.7M | 23.7M | May 1, 2023 | Common Stock | 23.7M | $0.27 | By PureTech Health LLC | F1, F3 | |||
| transaction | GLSH | Warrants | Purchase | +192M | 192M | May 1, 2023 | Common Stock | 192M | $0.02 | By PureTech Health LLC | F3 |
| Id | Content |
|---|---|
| F1 | Pursuant to a Note and Warrant Purchase Agreement, on February 21, 2023, the Issuer issued to PureTechHealth LLC convertible notes in an aggregate principal amount of $5,000,000 as well as warrants to purchase 23,688,047 shares of common stock. At the time of issuance, both the conversion of the convertible notes and exercise of the warrants was subject to the Issuer first receiving stockholder approval for the issuance of the underlying shares of common stock. On May 1, 2023, the Issuer and the Reporting Persons amended the terms of the convertible notes and warrants to remove this restriction on conversion and exercise, respectively. |
| F2 | The number of shares underlying the convertible notes reported herein is based on the outstanding principal amount plus accrued and unpaid interest as of April 30, 2023, and such number is subject to adjustment in accordance with the terms of the convertible notes. |
| F3 | The warrants were issued in connection with the purchase of the convertible note purchases reported herein |